InMed Pharmaceuticals News

Press Releases

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

May 15, 2023

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

March 28, 2023

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

March 13, 2023

InMed to Participate in Upcoming Investor Events

March 7, 2023

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 17, 2023

InMed Submits Form 12b-25

February 9, 2023

InMed Provides Business Update and Milestones for 2023

January 10, 2023

InMed Announces Results of 2022 Annual General Meeting

December 15, 2022

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

December 12, 2022

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

November 21, 2022

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

November 18, 2022

InMed Provides Update on Management Changes

November 17, 2022

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding

November 16, 2022

InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

November 11, 2022

Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022

November 10, 2022

InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week

October 26, 2022

InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

September 23, 2022

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

September 13, 2022

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

September 9, 2022

InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

September 8, 2022

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Press Releases

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

InMed to Participate in Upcoming Investor Events

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

InMed Submits Form 12b-25

InMed Provides Business Update and Milestones for 2023

InMed Announces Results of 2022 Annual General Meeting

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

InMed Provides Update on Management Changes

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding

InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022

InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week

InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive emails from InMed Pharmaceuticals